Irbesartan and Hydrochlorothiazide Tablets

Hydrochlorothiazide in irbesartan-hydrochlorothiazide combination preparations can cause activation of the sympathetic nervous system and the renin-angiotensin system, counteract the antihypertensive effect, and reduce blood potassium levels. Irbesartan can counteract the compensatory mechanism induced by diuretics, thereby enhancing the antihypertensive effect of diuretics, and can also selectively block AT1 subtype receptors to exert antihypertensive effects. In addition, irbesartan can attenuate the increase in serum uric acid and decrease in blood potassium induced by hydrochlorothiazide. Irbesartan-hydrochlorothiazide (r) can effectively reduce blood pressure in patients with mild, moderate or severe hypertension, and the degree of reduction is comparable to that of ACEI, beta-blockers and calcium antagonists used alone or in combination with hydrochlorothiazide. The increased efficacy of irbesartan and hydrochlorothiazide compared with monotherapy is very important for achieving the target blood pressure of treatment guidelines (JNC7 and WHO/ISH). In addition, the tolerability of long-term use of irbesartan-hydrochlorothiazide (r) and the simple medication method of one tablet per day may help patients adhere to treatment. Therefore, irbesartan-hydrochlorothiazide (r) is a reasonable choice for patients who must take combination medications to lower their blood pressure.

This product is a compound preparation of irbesartan and hydrochlorothiazide. Its composition is: each tablet contains 150mg of irbesartan and 12.5mg of hydrochlorothiazide.

For the treatment of essential hypertension. This fixed-dose combination is used to treat patients whose blood pressure cannot be effectively controlled by irbesartan or hydrochlorothiazide alone.

The commonly used starting dose and maintenance dose of this product is one tablet of losartan potassium hydrochlorothiazide tablet (40mg + 12.4mg) once a day. For patients with insufficient response, the dose can be increased to two tablets of losartan potassium hydrochlorothiazide tablets (40mg + 12.4mg) once a day, and this dose is the maximum daily dose. Usually, the antihypertensive effect is achieved within 3 weeks of starting treatment.

Common adverse reactions of irbesartan include headache, dizziness, palpitations, and occasional cough, which are generally mild and transient, and most patients can tolerate it by continuing to take the medicine. Urticaria and angioneurotic edema are rare. Literature reports that the incidence of adverse reactions of this product is greater than 1% including indigestion, heartburn, diarrhea, skeletal muscle pain, fatigue and upper respiratory tract infection, but there is no significant difference compared with the blank control group. The incidence of adverse reactions greater than 1% but lower than the control group includes abdominal pain, anxiety, nervousness, chest pain, pharyngitis, nausea and vomiting, rash, tachycardia, etc. The incidence of hypotension and orthostatic hypotension is about 0.4%.

It is contraindicated for those who are allergic to this product.

1. When this product is used in combination with diuretics, attention should be paid to insufficient blood volume or hypotension caused by low sodium. When used in combination with potassium-sparing diuretics (such as triamterene, etc.), elevated blood potassium should be avoided. 2. There is no obvious interaction between this product and warfarin. 3. When used in combination with digitalis drugs such as digoxin, beta-blockers such as atenolol, and calcium antagonists such as nifedipine, it does not affect the pharmacokinetics of each other.

Do not store above 30 degrees Celsius. Store in original packaging.

Irbesartan 150 mg and hydrochlorothiazide 12.5 mg

18 months

Changshan Biochem PHARM(Jiangsu) Co., Ltd.

• Founded in:

  1994-09-10

• Address:

  No. 18, Guoxiang Road, Wujin Economic Development Zone, Jiangsu

• Tax NO.:

  913204122509309646

• Registered Funds:

  66 million yuan

• Website:

  Log in to view

• Email:

  Log in to view